Yes, Kevzara (sarilumab) is a biologic medication. Specifically, it is a fully human monoclonal antibody, which means it was designed to precisely target and block a single molecule involved in inflammation. The FDA approved it as a biologic for treating rheumatoid arthritis, and it has since gained additional approvals for polymyalgia rheumatica and polyarticular juvenile idiopathic arthritis.
What Makes Kevzara a Biologic
Biologics are a distinct class of drugs made from living cells rather than synthesized through chemical reactions like traditional pills. Kevzara is produced using genetically engineered mice (developed with a technology called VelocImmune) that were designed to generate fully human antibodies. Because the drug originates from a biological system and is a large, complex protein molecule, it meets the FDA’s definition of a biologic and was approved through a Biologics License Application (BLA) rather than the standard new drug application used for conventional medications.
This distinction matters for a few practical reasons. Biologics are typically injected rather than taken by mouth because the proteins would break down in your digestive system. They also tend to be more expensive to manufacture than traditional drugs. And when patents expire, competitors can only make “biosimilars” (not exact generic copies), because replicating a complex biological molecule precisely is far more difficult than copying a chemical formula. As of 2024, no biosimilars for Kevzara have been approved by the FDA.
How Kevzara Works
Kevzara targets a protein called the interleukin-6 receptor (IL-6R). IL-6 is a chemical messenger that drives inflammation in conditions like rheumatoid arthritis. In a healthy immune response, IL-6 plays a useful role, but when it’s overactive, it fuels the joint swelling, pain, and damage that characterize inflammatory arthritis.
Kevzara works by physically attaching to IL-6 receptors, both those sitting on the surface of cells and those floating freely in the bloodstream. Once Kevzara binds to the receptor, IL-6 can no longer dock there and trigger its inflammatory cascade. This is a more targeted approach than older drugs that broadly suppress the immune system. It belongs to a subclass of biologics known as IL-6 receptor inhibitors, alongside tocilizumab (Actemra).
Conditions It Treats
Kevzara is FDA-approved for three conditions:
- Rheumatoid arthritis in adults who haven’t responded well enough to other disease-modifying drugs. It can be used in combination with methotrexate or similar medications, or on its own.
- Polymyalgia rheumatica, an inflammatory condition causing widespread muscle pain and stiffness, particularly in the shoulders and hips.
- Polyarticular juvenile idiopathic arthritis, a form of childhood arthritis affecting multiple joints.
For rheumatoid arthritis, biologics like Kevzara are generally considered after conventional disease-modifying drugs (like methotrexate) haven’t provided enough relief. They’re not typically first-line treatments.
How It’s Administered
Kevzara comes as a pre-filled syringe that you inject under the skin (subcutaneously) once every two weeks. The standard dose is 200 mg. If blood work shows certain side effects like low white blood cell counts or elevated liver enzymes, the dose may be reduced to 150 mg every two weeks. Many people learn to self-inject at home after initial guidance.
Common Side Effects
Because Kevzara partially suppresses part of the immune system, the most notable side effects relate to infection risk and changes in blood counts. In clinical trials for rheumatoid arthritis, the most frequent reactions (occurring in at least 3% of patients) were low white blood cell counts (neutropenia), elevated liver enzymes, redness at the injection site, upper respiratory infections, and urinary tract infections.
Neutropenia deserves specific mention. In trials, 6% of patients on the 200 mg dose experienced a meaningful drop in a type of white blood cell called neutrophils. This is why regular blood monitoring is part of treatment with Kevzara, especially in the early months. Your provider will check blood counts and liver function periodically to catch any changes early.
Kevzara also affects cholesterol levels. Within the first four weeks of treatment, LDL (“bad” cholesterol) rose by an average of 12 to 16 mg/dL, and triglycerides increased by 20 to 27 mg/dL. HDL (“good” cholesterol) went up modestly by about 3 mg/dL. These shifts are generally manageable but mean lipid levels should be checked after starting the drug.
In polymyalgia rheumatica trials, side effects followed a similar pattern: neutropenia was the most common at 15.3%, along with low white blood cell counts more broadly (6.8%), fatigue (5.1%), and itching at the injection site (5.1%).
How Kevzara Compares to Other Biologics
Kevzara is one of many biologic options for rheumatoid arthritis, and the biologics on the market work through different mechanisms. TNF inhibitors (like adalimumab and etanercept) block a different inflammatory molecule called tumor necrosis factor. Kevzara and tocilizumab both target IL-6 signaling instead. Other biologics target B cells, T cell signaling, or other parts of the immune pathway.
The choice between biologics often comes down to individual response, side effect profile, and practical factors like how the drug is given. Some patients who don’t respond to a TNF inhibitor will respond to an IL-6 blocker like Kevzara, and vice versa. Kevzara’s every-two-week self-injection schedule is comparable to many other biologics in terms of convenience. One distinguishing feature is that Kevzara is a fully human antibody rather than a humanized or chimeric one, which can reduce the likelihood of the body developing antibodies against the drug itself.